Drew J. Winston

Infectious Disease
13351 Riverside Dr Ste D
Sherman Oaks, CA 91423

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications

Real-world clinical impact of plasma cell-free DNA metagenomic next-generation sequencing assay.

Real-world clinical impact of plasma cell-free DNA metagenomic next-generation sequencing assay.

Journal: Infection control and hospital epidemiology
Published: January 30, 2025

Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection.

Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection.

Journal: The Journal of infectious diseases
Published: July 05, 2024

AURORA: A New Dawn.

AURORA: A New Dawn.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: April 04, 2024

Cytomegalovirus immunity in high-risk liver transplant recipients following preemptive antiviral therapy versus prophylaxis.

Cytomegalovirus immunity in high-risk liver transplant recipients following preemptive antiviral therapy versus prophylaxis.

Journal: JCI insight
Published: February 16, 2024

Good Outcomes in Therapy of Fusariosis Depend on Both an Effective Drug and the Host.

Good Outcomes in Therapy of Fusariosis Depend on Both an Effective Drug and the Host.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: January 04, 2024

Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.

Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: August 09, 2023

Transient SARS-CoV-2 RNA-Dependent RNA Polymerase Mutations after Remdesivir Treatment for Chronic COVID-19 in Two Transplant Recipients: Case Report and Intra-Host Viral Genomic Investigation.

Transient SARS-CoV-2 RNA-Dependent RNA Polymerase Mutations after Remdesivir Treatment for Chronic COVID-19 in Two Transplant Recipients: Case Report and Intra-Host Viral Genomic Investigation.

Journal: Microorganisms
Published: June 29, 2023

Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant.

Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant.

Journal: Open forum infectious diseases
Published: March 29, 2023

Fosmanogepix Therapy of Disseminated Fusarium Infection.

Fosmanogepix Therapy of Disseminated Fusarium Infection.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: March 23, 2023

Utilization of whole genome sequencing for resolution of discrepant Mycobacterium tuberculosis drug susceptibility results: A case report.

Utilization of whole genome sequencing for resolution of discrepant Mycobacterium tuberculosis drug susceptibility results: A case report.

Journal: IDCases
Published: August 20, 2021

Association of HHV-6 With Outcomes in CMV-seronegative Liver Transplant Recipients With CMV-seropositive Donors Receiving Preemptive Antiviral Therapy.

Association of HHV-6 With Outcomes in CMV-seronegative Liver Transplant Recipients With CMV-seropositive Donors Receiving Preemptive Antiviral Therapy.

Journal: Transplantation
Published: February 15, 2021

Unexpected Cytomegalovirus (CMV) Replication Kinetics in CMV Donor-Seropositive, Recipient-Seronegative Liver Transplant Recipients Receiving Preemptive Antiviral Therapy.

Unexpected Cytomegalovirus (CMV) Replication Kinetics in CMV Donor-Seropositive, Recipient-Seronegative Liver Transplant Recipients Receiving Preemptive Antiviral Therapy.

Journal: The Journal of infectious diseases
Published: January 26, 2021
Showing 1-12 of 37

Last Updated: 09/26/2026